FDA Detention Sampling — Frequently Asked Questions

An FDA import detention is a hold placed on an imported shipment when the U.S. Food and Drug Administration has reason to believe the product may violate the Federal Food, Drug, and Cosmetic Act. The shipment cannot enter U.S. commerce while detained, and the importer is given an opportunity to respond with evidence or testimony before FDA makes its admissibility decision.

An FDA Notice of Action is the official document FDA issues about an import entry, stating that the shipment has been detained, the charge (the suspected violation), the entry and line numbers affected, and the deadline for responding with evidence or testimony.

It is the first document to provide at intake, because the sampling and testing plan is built around what the notice says.

A detention is a hold with an opportunity to respond: FDA believes the shipment may violate the law and gives the importer a window to present evidence. A refusal is the outcome if the response fails or never comes — the shipment must then be exported or destroyed under the applicable procedures.

The window between the two is where sampling and testing work happens.

The response deadline is stated on your FDA Notice of Action and is case-specific. Extensions may be possible in some circumstances through the appropriate channels, typically handled by your customs broker, regulatory consultant, or attorney.

Treat the printed deadline as real — laboratory methods have fixed durations, so earlier sampling means more of the window fits your evidence.

A detention does not mean FDA proved a violation — it means FDA has a basis to suspect one, which can come from examination, sampling, documentation review, the product category's history, or an import alert covering the product or supplier. Compliant goods are detained regularly, especially under import alerts, where detention is automatic.

That is precisely what independent testing is for: producing evidence about your actual shipment rather than the category's reputation.

No. The detention stays in place until FDA makes its decision on the entry. The shipment typically remains at its holding facility under the applicable custody requirements while the response is prepared and reviewed.

If no adequate response is submitted by the deadline, FDA can refuse the entry, and refused goods must generally be exported or destroyed under the applicable procedures — often with the costs falling on the importer.

Doing nothing is itself a decision, and usually the most expensive one.

A private laboratory analysis is testing of the detained product performed by an independent, non-government laboratory at the importer's initiative, used as evidence that the shipment does not bear the violation charged. FDA evaluates the analysis together with how the samples were collected, identified, and handled.

That is why the sampling plan and chain of custody matter as much as the laboratory work itself.

Three things: read the notice and note the charge, entry number, and deadline; confirm where the shipment is physically held and obtain the facility contact; and alert your customs broker and, if you use one, your regulatory consultant or attorney.

If testing may be part of the response, start that conversation the same day. You can submit your documents for review immediately.

FDA issues detentions for suspected violations of the laws it administers, while U.S. Customs and Border Protection (CBP) processes the entry itself and can place its own separate holds. The two agencies coordinate on imports, but an FDA Notice of Action is an FDA action.

Your customs broker can tell you which agency has acted on your entry and what each hold requires.

The entry number is the unique identifier assigned to your import entry in the customs process. It ties together the shipment, the FDA notice, the broker's filings, and any response — so every party in a detention case uses it to make sure they are talking about the same goods.

It appears on your Notice of Action and your broker's entry documents.

Yes. Detentions are issued at the entry line level, so FDA can detain specific products or lines while others on the same entry proceed. Your Notice of Action identifies exactly which lines are affected.

Sampling plans are built around the detained lines and lots — not the shipment as a whole.

Testimony is the evidence and argument the importer submits to show the shipment should be admitted — documents, records, analysis results, and explanations responsive to the charge. Independent laboratory results with chain-of-custody documentation are a common component.

What your specific response should include is a strategy question for your broker, consultant, or attorney.

No. A detention is a hold on one specific entry, not a ban on the product. The same product can be admissible in other entries, and even the detained entry can be released if the response succeeds.

An import alert is broader — it presumptively affects future shipments — but even that is not a ban; each entry can still be defended.

Exporting or destroying the goods under the applicable procedures is generally what happens after refusal, and in some situations an importer may choose not to contest a detention. Whether that is the right business decision depends on the shipment's value against the cost and likelihood of a successful response.

That cost-benefit conversation is worth having honestly at intake — sometimes testing is not the rational choice, and you should be told so.

It can. Detention history is part of what informs FDA's screening, and repeated violations can contribute to a firm or product being added to an import alert — at which point future shipments can be detained automatically.

That is one reason resolving a detention with solid evidence, rather than abandoning entries, can matter beyond the single shipment.

An FDA hold (detention) concerns suspected violations of FDA-administered laws — product safety, adulteration, misbranding. A CBP hold concerns customs matters — classification, valuation, admissibility under customs law, or inspection. A shipment can be subject to both.

Your customs broker can identify which holds are on your entry; FDA detention sampling addresses the FDA side.

Sometimes. Movements of detained cargo are subject to the applicable procedures and are typically arranged through your customs broker. Where a transfer is permitted, sampling coordination adapts to the new facility.

Whether a move helps or hurts your timeline depends on the case — worth discussing with your broker before assuming.

The charge is stated on your FDA Notice of Action — it identifies the suspected violation in regulatory language. If the wording is unclear, your broker, consultant, or attorney can interpret it, and it is one of the first things reviewed at intake.

The charge determines everything downstream: what to test, by what method, and what evidence the response needs.

Reconditioning is a separate pathway in which an importer may request FDA authorization to bring a non-compliant shipment into compliance — for example, by relabeling or reprocessing — under an approved plan. It applies in some situations and not others.

Whether reconditioning, testing, or another response fits your case is a strategy decision for your regulatory advisor; we coordinate the sampling and testing side.

Not always, but often it helps — and for import alert matters, petitions, or ambiguous charges, professional strategy is usually essential. Straightforward cases are sometimes handled by the importer and broker with testing evidence alone.

We are not a law firm and do not give legal advice; we coordinate evidence and work alongside whichever professionals your case needs.

Your broker manages the entry with CBP and FDA systems, typically receives and transmits notices, helps authorize activity related to the entry, and often submits the response package. In most cases the broker is the operational hub between you, the facility, and the agencies.

Sampling coordination works alongside your broker — their contact information is requested at intake.

It means FDA has flagged the entry for screening or examination and has not yet made an admissibility decision. A hold or review is not yet a detention — many entries are reviewed and proceed without any Notice of Action being issued.

If a detention does issue, the Notice of Action will state the charge and deadline; that is the point where evidence planning begins.

Detained cargo is held by the facility where it sits — warehouse, cold storage, or container freight station — under that facility's procedures and the applicable custody requirements. Storage conditions are the facility's operational responsibility, billed under its terms.

For temperature-sensitive goods, confirming the storage conditions early matters twice over: for the product's condition and for the validity of any later testing.

Sometimes. Depending on the charge, responses may rest on documentation, labeling corrections, reconditioning, or other evidence rather than analysis. Testing is the common path for contamination, residue, identity, and similar charges — not every charge.

If your case does not actually need testing, you should hear that at intake rather than be sold a service.

FDA laboratory testing coordination is the work of matching a detained shipment's case to a suitable independent laboratory — the right analysis for the detention charge, a validated method, adequate capacity, and any required accreditation — and managing the sample logistics between the cargo and the laboratory bench.

The laboratories are independent and issue their own reports; coordination never touches the science.

No — “FDA-approved laboratory” is not a real designation, and companies using that phrase are being loose with the truth. FDA does not broadly approve private laboratories. What exists are independent laboratories with recognized accreditations, and FDA's LAAF program, which accredits laboratories for specific covered food-testing purposes.

LAAF is FDA's Laboratory Accreditation for Analyses of Foods program. For certain food testing — including, in specified circumstances, testing conducted to support admission of detained food — FDA may require the analysis to be performed by a LAAF-accredited laboratory, and results from a non-qualifying lab may not be usable for that purpose.

Whether LAAF applies depends on your product and situation. It is confirmed during laboratory matching, before collection.

The detention charge on your FDA Notice of Action drives the answer: a Salmonella charge points to pathogen analysis, a pesticide charge to residue screens, an identity question to composition or authenticity work. The analysis is then matched to a validated method and a laboratory whose scope covers it.

Four broad families cover most detention cases: microbiological testing (pathogens and indicator organisms), chemical testing (pesticides, heavy metals, additives, residues, mycotoxins), identity and composition testing (authenticity, potency, species), and product-condition evaluation (container integrity, decomposition, filth).

Availability for a specific product depends on laboratory capabilities, validated methods, and sample quantity.

Microbiological testing analyzes the product for microorganisms — pathogens such as Salmonella or Listeria, and indicator organisms that signal sanitation problems. It is the most common testing family for foods detained on contamination charges.

Many microbiological methods include incubation periods with fixed durations, which is why these analyses set the floor on turnaround time.

Chemical testing analyzes the product for substances — pesticide residues, heavy metals such as lead or cadmium, mycotoxins such as aflatoxin, unapproved additives or colors, and drug residues in aquaculture products. The specific panel follows the detention charge.

Chemical analyses are matched to validated methods and detection limits appropriate to the charge.

Identity testing confirms a product is what it claims to be — the declared species of a seafood product, the declared ingredient in a supplement, the declared composition of an oil. It answers substitution, adulteration, and misdeclaration charges.

Methods range from compositional profiling to species identification, chosen for the product and question.

A filth examination is a laboratory analysis for foreign matter — insect fragments, rodent evidence, and other contamination indicating insanitary conditions. Filth is one of the most common charges for spices, grains, and similar commodities.

It is a distinct analysis with its own methods and sample requirements, planned like any other test.

Reputable analytical laboratories typically hold accreditations such as ISO/IEC 17025 for the competence of testing laboratories, with defined scopes listing the methods they are accredited to perform. For certain food testing, FDA's LAAF accreditation may additionally be required.

Laboratory matching includes confirming that the lab's accreditation scope actually covers your analysis — not just that a certificate exists.

A validated method is an analytical procedure whose reliability has been demonstrated for the specific analyte and product type. Results from an appropriate validated method carry evidentiary weight; results from an unvalidated or mismatched method invite challenge.

Method fit is confirmed with the laboratory during matching — one of the quiet details that decides whether testing money is well spent.

Generally not as a substitute. A supplier's COA describes testing done elsewhere, on other samples, outside your custody — it does not demonstrate that your detained shipment complies. Detention responses typically rest on analysis of samples collected from the detained lot itself, under documented custody.

Your advisors may still include supplier documentation as supporting evidence; that is a strategy question for them.

Sometimes. Where a case needs multiple analyses, one laboratory may cover them all, or the work may need to be split across laboratories with different scopes. Splitting is normal and is coordinated with custody documentation for each destination.

The full testing picture is mapped at intake so sample quantities and logistics are planned once.

The laboratory will report that it cannot complete the analysis, and re-sampling is usually required — a delay measured in days. This is the most preventable failure in the process, which is why quantity requirements are confirmed with the laboratory before collection, never after.

Possibly — depending on retained sample material, laboratory policies, and what your advisors decide. Repeat or follow-up analysis is a case-by-case decision with cost and timeline consequences.

This is one reason laboratory retention policies and adequate sampling quantities are considered up front.

Laboratory reports are issued by the laboratory itself and typically include sample identification tied to the custody record, the methods used, the results with applicable detection limits, and the laboratory's accreditation identifiers. Formats vary by laboratory.

The report arrives organized with the custody records and photographs into your case file.

Yes. Independent laboratories cover cosmetics (color additives, microbials, heavy metals), dietary supplements (identity, potency, contaminants), OTC drug products (assay, impurities), and food contact materials (migration, lead and cadmium), among others.

Availability for a specific product and analysis is confirmed during matching.

By coordinated courier with tracking, packaged to the laboratory's specifications — leak-resistant containment, and refrigerated or frozen transport where the product requires it. Every transfer is signed and time-stamped, and the laboratory documents arrival condition, seal integrity, and temperature.

Receiving hours and cut-offs are confirmed in advance so cold-chain samples never sit on a dock over a weekend.

Total time is the sum of three clocks: coordination (compressible), third parties like courier transit and laboratory queues (partly compressible), and the method itself — certain microbiological analyses have fixed incubation periods no rush fee can shorten.

Once your case is defined, you receive the laboratory's actual turnaround estimate rather than a marketing number.

Some laboratories offer rush service for some analyses at added cost, which compresses queue time — not method time. Whether rush service exists for your analysis, and what it costs, is confirmed during laboratory matching.

Flag your FDA deadline at intake so rush options are evaluated from the start.

Candidate laboratories are identified during matching based on the required analysis, method, capacity, and accreditation, and the proposed plan comes back to you for review before work begins. If you or your advisors have a preferred laboratory, that preference is factored in.

What matters is that the chosen lab's scope actually fits the case — that check happens regardless of who proposes the name.

Yes — where a regulatory professional is engaged, their strategy typically directs what is tested and to what standard, and coordination executes to that direction. The case file is organized so they can use it.

Their contact information is requested at intake precisely so this alignment happens early.

The result is yours. It is reported to you and your authorized parties, and nothing is submitted to FDA automatically. What to do next — further analysis, a different response, or accepting the outcome — is a decision for you and your advisors.

No honest coordinator can promise a passing result.

Results go to you and the parties you authorize — typically your customs broker, regulatory consultant, or attorney — organized with the custody records into a usable case file. Nothing is transmitted to FDA automatically.

Whether and how results are submitted to FDA is a decision for you and your authorized parties.

FDA evaluates private laboratory results on their merits, considering the analysis itself and how the samples were collected, identified, and handled — and no private party can guarantee acceptance. A complete, credible package is what gives results their best chance of being weighed as intended.

FDA makes the final admissibility decision on its own review, on every entry.

Costs come in two layers: coordination services, and third-party charges billed by the parties performing the physical and analytical work — sampler fees, warehouse handling charges, laboratory fees, courier costs, and extras like temperature-controlled shipping or rush service where applicable.

Whenever possible, the complete picture is reviewed with you before work begins. Costs vary too much by product, tests, and location for an honest flat number to exist.

Because the biggest cost drivers are unknown until the case is defined: which analyses the charge requires, how many samples the method needs, whether cold chain is involved, what the warehouse charges for access, and which laboratory fits. A number quoted before those facts is a guess dressed as a quote.

Third-party charges are fees billed by the independent parties that perform work in your case — the warehouse for access and handling, the sampler for collection, the laboratory for analysis, and the courier for transport. They are set by those parties, and applicable charges are identified as your plan is defined.

The analyses themselves: how many tests, which methods, how many lots must be tested separately, whether accredited (e.g., LAAF) capacity is required, and whether rush service is used. A single-lot, single-analysis case and a multi-lot, multi-panel case are different projects.

The laboratory quotes its own fees; those numbers are part of the scope reviewed with you.

Typically the collection visit itself — time on site, travel where applicable, and materials such as containers and seals. Fees vary with location, product handling requirements, and the size of the collection.

Sampler charges are among the third-party costs identified for your case up front.

Facilities commonly bill for the labor and logistics of making detained cargo available for sampling — moving pallets, opening containers, supervising access — under their own tariffs. Some facilities charge more than others for the same work.

These are facility charges, not ours; they are flagged as part of your case's cost picture as they are identified.

Standard sample transport is usually a modest line item; refrigerated or frozen shipping with validated packaging costs more and constrains timing. Distance to the chosen laboratory matters too.

Where cold chain applies, transport is planned and priced as part of the scope rather than improvised.

Some laboratories offer rush service at added cost, which compresses queue time — not method time. Whether it is worth it depends on your FDA deadline: paying to save two queue days can matter enormously or not at all.

That calculation is made against your actual deadline during planning.

Sometimes, yes — particularly for low-value shipments needing multiple analyses. When the numbers do not make sense, you should be told plainly at intake so you can decide with clear eyes, including whether not contesting the detention is the rational choice.

An honest cost conversation before work begins is part of the service.

Payment terms are set out in your engagement scope before work begins, including how third-party charges are handled. Nothing should be a surprise mid-case — if it would be, it belongs in the scope conversation.

Ask anything about billing at intake; clear answers there are a good test of any vendor.

Often there are efficiencies — one sampling visit can feed several analyses if quantities permit, one courier run serves multiple tests at the same laboratory, and planning everything at once avoids re-sampling. The laboratory fees themselves are per-analysis.

This is why the full testing picture is mapped at intake rather than discovered one test at a time.

Because the third parties vary: warehouse tariffs differ by facility, sampler travel differs by geography, courier lanes differ in distance and cold-chain options, and laboratory proximity differs by market. Dense import markets tend to have more competitive options.

Location is one of the first facts collected at intake for exactly this reason.

Storage and related facility charges during a detention are generally the importer's responsibility, billed by the facility holding the cargo under its own terms. They accrue for as long as the shipment sits.

That running cost is one of the strongest practical arguments for starting the evidence work immediately.

No — storage accrues until the shipment leaves the facility, whatever the reason. Submitting a response does not pause facility billing, and FDA's review takes whatever time it takes.

Factor continued storage into the cost picture when deciding how to proceed.

There is no honest universal number. The timeline is the sum of coordination time (compressible with complete information and early facility contact), third-party time (partly compressible), and method time (fixed — some analyses simply take days by design).

The realistic case-specific picture comes once the plan is defined. The process page breaks down where time is won and lost.

Once scheduled and authorized, the collection visit is usually the short part — commonly a matter of hours on site, depending on shipment size, lot structure, and facility logistics. The days are spent in scheduling and authorization, not at the pallet.

That is why the facility contact is the most valuable single item you can provide at intake.

Domestic sample transport typically runs overnight to a few days depending on distance and service level; cold-chain shipments are planned within the packaging's validated transit window. Laboratory receiving hours and cut-offs are confirmed so samples never sit over a weekend.

Transport is one of the partly compressible clocks — paying for faster service is sometimes worth it against a deadline.

As a family, microbiological analyses tend to set the floor, because many methods include incubation periods with fixed durations. Chemical and identity analyses vary with method and laboratory queue.

Your laboratory's turnaround estimate for the specific methods is provided once the case is defined — that number, not a generality, is what to plan around.

Fastest, when done right: intake and planning — largely within your and our control. Slowest, most often: facility authorization and method-mandated laboratory time. One is addressable with early contact; the other is physics and procedure.

Knowing which clock is running lets you push where pushing works.

No. The deadline on your Notice of Action runs regardless of what your evidence work is doing. If results will not be ready in time, extension requests through the appropriate channels are a matter for your broker, consultant, or attorney.

This is why the testing conversation should start the day the notice arrives.

Tell your broker or advisor immediately — extension requests, where available, are handled through the appropriate channels, and the earlier they are raised the better. Planning the analysis timeline against the printed deadline is part of case definition.

No coordinator can promise an extension; what coordination does is surface the timing conflict early enough to act on it.

The coordination layer, yes — complete first submissions, early warehouse contact, parallel scheduling, and pre-confirmed laboratory requirements save real days. Some laboratories offer rush service at added cost. Method-mandated incubation periods cannot be shortened by anyone, at any price.

Urgent detention matters receive priority intake review — flag your deadline when you submit.

The expensive failures: re-sampling because quantities were wrong, unusable results from a mismatched or non-qualifying laboratory, cold-chain breaks that void an analysis, weekend dock time, and duplicated site visits. Each is prevented by confirming requirements before acting.

Coordination cannot make third parties free — it makes their work count the first time.

Because it repeats nearly everything: facility authorization and handling, sampler time and travel, courier transport — plus the days lost against your deadline and the storage that accrued meanwhile. It is the single most expensive avoidable event in the process.

Confirming laboratory requirements before the first visit exists to prevent exactly this.

Submit the FDA Notice of Action, product details, lot structure, shipment location, and facility contact. With those facts, the required analyses, laboratory fit, and known third-party charges can be laid out for your review before you commit to anything.

Start at Request Sampling Assistance.